Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trialRevolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.{}

Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, the company said.https://www.cnbc.com/2026/04/13/pancreatic-cancer-drug-daraxonrasib-from-revolution-medicines-succeeds-in-trial.html